Tag: Novo Nordisk A/S

Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Hims & Hers pulls copycat weight-loss pill after threats of legal action

White House to launch direct-to-consumer drug site Trump Rx. Here’s what to know

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections